热门资讯> 正文
Cellectar收到纳斯达克公司的违约通知信，以重述财务报表
2024-08-24 05:27
- Cellectar Biosciences (NASDAQ:CLRB) on Friday said it has received a delinquency notification letter from Nasdaq.
- The notice indicated that the company is not in compliance with the periodic financial report filing requirement set forth in Nasdaq listing rules as a result of the company's delay in filing its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024.
- The delay in filing the Second Quarter 10-Q is a result of the company’s need to restate certain previously filed financial statements. The financial statement changes are all expected to be non-cash and non-operating.
- CLRB +1.36% after hours to $2.149.
- Source: Press Release
More on Cellectar Biosciences
- Cellectar: WM Treatment Data Leads To A Few Regulatory Milestones
- Cellectar Biosciences reports Q2 results
- Cellectar Biosciences Q2 2024 Earnings Preview
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
